Korea has cut generic prices to 45% of the originator price and opened confidential net pricing. For companies entering through a local partner, the reform changes who is worth partnering with, and what the contract needs to say.

On 18 September, Beijing published its industrial blueprint for pharmaceuticals and medical devices. Read against the results of the previous plan, it tells European companies and Chinese innovators two different but complementary things.